| Customization: | Available |
|---|---|
| Transport Package: | Drum |
| Specification: | 99% |
|
Still deciding? Get samples of US$ 50/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Irofulven, also known as 6-hydroxymethylacylfulvene (HMAF) or MGI-114, is a semisynthetic anticancer agent derived from the toxic jack-o-lantern mushroom. It is a member of the acylfulvene class of compounds, which are known for their potent antitumor activity. Irofulven has been the subject of numerous clinical trials due to its unique mechanism of action and potential to overcome resistance observed in other chemotherapeutic agents.
The mechanism of action of irofulven involves rapid absorption by tumor cells, where it binds to DNA and protein targets. This binding interferes with DNA replication and cell division of tumor cells, leading to tumor-specific apoptotic cell death, or "cell suicide." The drug is bioactivated by the NADPH-dependent enzyme alkenal/one oxidoreductase (AOR), which is highly expressed in many tumors. This process results in the formation of a reactive metabolite that can alkylate DNA, causing double-strand breaks and leading to cell death.
In terms of pharmacokinetics, irofulven has been shown to have a short elimination half-life and is rapidly cleared from the body. The drug's absorption, distribution, metabolism, and excretion profiles are not fully available, but it is known to be metabolized in the liver and excreted through the kidneys.
In summary, irofulven is a unique anticancer agent with a distinct mechanism of action that has shown potential in treating a variety of cancers. Ongoing research and development efforts are focused on enhancing its clinical utility and reducing its side effects.
){kind=link}